CStone Pharmaceuticals
Tao Wu has extensive experience in the pharmaceutical industry. Tao served as an Associate Director of Clinical Science at Kaishi Pharmaceutical from 2019 to the present. Prior to this, they held various roles at Eli Lilly China, including Associate Director of Scientific Communication from 2018 to 2019, Senior Medical Communication Manager from 2016 to 2017, and Medical Communication Manager from 2014 to 2016.
Tao Wu completed a Bachelor's degree in Medicine and Surgery (M.B.B.S.) from Fudan University from 2001 to 2006. Following that, from 2008 to 2013, Tao Wu pursued a PhD in Immunology at The University of Connecticut Health Center.
CStone Pharmaceuticals
CStone is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established at the end of 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. With a strategic emphasis on immuno-oncology combination therapies, the Company has built an oncology-focused pipeline of 16 drug candidates, including 5 late-stage candidates at pivotal trials or registration stages. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStone’s vision is to become a world-renowned biopharmaceutical company that is leading the way to conquering cancer.